Takeda and Seattle Genetics Highlight Post-Hoc Analysis Examining Progression-free Survival with ADCETRIS A Versus Prior Therapy at the International Conference on Malignant Lymphoma aS' Analysis showed more than 60 percent of patients achieved longer progression-free survival following treatment with ADCETRIS compared to prior therapy aS' ... (more)
http://eon.businesswire.com/news/eon/20130619005639/en/Takeda-Seattle-Genetics-Highlight-Post-Hoc-Analysis-Examining
http://eon.businesswire.com/news/eon/20130619005639/en/Takeda-Seattle-Genetics-Highlight-Post-Hoc-Analysis-Examining
No comments:
Post a Comment